A Phase 2 interventional study of RC28-E injection in Diabetic Retinopathy, sponsored by RemeGen Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-11.
Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Diabetic Retinopathy with a site in China — 26 open to participants now, 27 under way, 2 of them phase 3. Diabetic Retinopathy · China.
Among the 83 studies in Diabetic Retinopathy with a site in China, this one is the 31st largest by planned enrollment of the 55 interventional ones that give a count, is one of 8 that started in 2021, is one of 5 in phase 2, and was the 42nd registered.
779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
Browse Diabetic Retinopathy studies →26 of the 83 studies in Diabetic Retinopathy with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Beletalent (Zhuhai) Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
Xuxiang Zhang, MD · Sites in China
Ages 40–80
Yufan Wang · Sites in China
Ages 20–79
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 7 · Phase 4 5
First in 2008; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.
Median enrollment 142 across the 55 interventional studies, 759 across the 28 observational. Of the 29 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 83 have an industry lead sponsor. The 10 most frequent:
RemeGen Co., Ltd. is the lead sponsor of 83 studies on the registry; 42 are open to participants now.
RemeGen Co., Ltd. has 1 study filed under Diabetic Retinopathy — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetic Retinopathy with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06272565Zhongshan Ophthalmic Center, Sun Yat-sen UniversityExploring the Interaction Between Metabolic Disorders and NLPR3 Inflammasome Activation in DR Inflammatory Damage | 2026-12-30 |
| NCT07201415Zhongnan HospitalMinimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma | 2026-12-31 |
| NCT06610747Zhongshan Ophthalmic Center, Sun Yat-sen UniversityHome- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 83 studies in Diabetic Retinopathy with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, open-label, multicenter study of the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
Biological: RC28-E injection
Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
Biological: RC28-E injection
Subjects received 2.0mg intravitreal RC28-E injection every 4 weeks for 3 visits followed by injections every 8 weeks.
Biological: RC28-E injection
Subjects received 1.0mg intravitreal RC28-E injection every 4 weeks for 5 visits followed by injections an as needed (PRN) schedule based upon the physician assessment in accordance with pre-specified criteria.
Biological: RC28-E injection
a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF
The proportion of subjects who have improved by ≥2 steps from baseline in DRSS score at week 24, 52
The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24, 52 from baseline
Time frame: At Week 24, 52
Percentage of Participants Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Week 24, 52
Vision-threatening complications are defined as the composite outcome of proliferative diabetic retinopathy (inclusive of participants who have vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and anterior segment neovascularization (ASNV) (participants with neovascularization of the iris and/or definitive neovascularization of the iridocorneal angle).
Time frame: At Week 24, 52
Percentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 24, 52;
The percentage of participants who developed CI-DME at week24, 52 were reported.
Time frame: At Week 24, 52
Mean Change from Baseline in Best Corrected Visual Acuity (BCVA);
Measurement of visual acuity with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.
Time frame: Baseline up to week 52
Mean change from baseline in DRSS score;
The Diabetic Retinopathy Disease Severity Scale (DRSS) may be used to describe overall retinopathy severity as well as the change in severity over time. Here, DRSS describes severity level 47 (moderately severe NPDR) and level 53 (severe NPDR) at week 24, 52 from baseline.
Time frame: Baseline upto week 52
Percentage of Participants Who Received Panretinal Photocoagulation (PRP) at Week24, 52;
The percentage of participants who received panretinal photocoagulation (PRP).
Time frame: At Week 24, 52
Percentage of participants who undergoing Vitrectomy at Week24, 52;
The percentage of participants who undergoing vitrectomy.
Time frame: At Week 24, 52
Frequency of administration RC28-E;
Number of intravitreal injections
Time frame: At Week 24, 52
Safety of RC28-E injection
Incidence of AE in ocular and non-ocular
Time frame: Baseline upto week 52
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2021 (actual). Primary completion is estimated for May 2024, 36 months after the start.
Of 30 industry-sponsored phase 2 interventional studies under Diabetic Retinopathy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 37. This study's planned 36 months is above that.
Counting every sponsor, half of 43 studies reached it within 31 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RC28-E protein